Articles tagged with Molecular Targets
Researchers studied the association of 12 immune cell types with epigenetic age acceleration in healthy and diseased populations. Their work sheds light on the complex interplay between immune cell composition and epigenetic aging.
Researchers have identified a signaling molecule called STAT4 that plays a crucial role in dendritic cells responding to inflammatory signals. This discovery could lead to the development of new therapeutics to modify immune responses and alleviate symptoms of diseases like multiple sclerosis.
Recent advances highlight PIK3CA mutation significance in determining targeted therapy efficacy, particularly in advanced breast cancer. Molecular signatures and genetic profiles drive personalized treatment strategies, with emerging therapies offering new hope for patients.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A recent study published in Cell Metabolism reveals a critical link between defects in the urea cycle and the development of fatty liver disease. The researchers found that these defects lead to secondary impairment in energy metabolism, resulting in excessive fat storage and inflammation in the liver.
The study identified 96 mutated driver genes, 9 of which were previously unknown in CRC, and 24 that were new to any form of cancer. A new molecular classifier system was developed, identifying five distinct CRC prognostic subtypes with unique molecular characteristics.
Researchers developed a simple, cost-effective method to study ubiquitination, a critical protein modification process involved in diverse cellular functions. The Ub-POD method quickly labels targets of E3 ligase enzymes directly in human cells, allowing for the identification of new substrates and expanding therapeutic options for dis...
Researchers have developed a new class of synthetic polymers that effectively combat fungal infections by attacking the cells in multiple ways. These compounds mimic naturally occurring peptides and offer potential for sustainable treatment options with improved survival rates.
Researchers at the University of Bologna have identified a specific location and genomic context where DNA breaks occur due to topoisomerase I inhibition. This discovery could lead to new cancer treatments by inducing DNA damage and genomic instability in cancer cells.
Scientists at St. Jude Children's Research Hospital found a link between a SARS-CoV-2 protein and the onset of multisystem inflammatory syndrome in children (MIS-C). A region of the SARS-CoV-2 nucleocapsid protein shares high sequence and immunogenic similarities to human protein SNX8, sparking an inflammatory response.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
Researchers found that children's immune systems attacked their own tissues after latching onto a coronavirus protein resembling one found in multiple organs. Early intervention was crucial to prevent death in these cases, and the study has implications for understanding other autoimmune diseases.
A study found that increased expression of human carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) on immune cells is associated with treatment-resistant melanoma. CEACAM1 is now considered a potential therapeutic target for patients with resistant tumors.
Researchers have developed a new therapy called PIPE-307 that targets an elusive receptor on certain cells in the brain, prompting them to mature into myelin-producing oligodendrocytes. This could potentially reverse damage caused by multiple sclerosis, leading to improved movement, balance, and vision.
Researchers at Dartmouth College have developed a self-powered pump that uses natural light and chemistry to target and remove specific water pollutants. The pump uses synthetic molecular receptors designed to bond to negatively charged ions, which are then trapped and released in a non-reactive substrate.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
Researchers at U of T mapped the spatial distribution of long non-coding RNAs in testes, finding higher levels than previously estimated. The study suggests lncRNAs play a more significant role in male reproduction and may influence sperm development and behavior.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
Researchers found that folded peptides are more electrically conductive than their unfolded counterparts due to the formation of a specific secondary structure called the 3_10 helix. This discovery has implications for the design and development of molecular electronic devices.
Researchers at the University of Illinois Chicago have developed a new dual-action antibiotic that targets two different cellular targets, making it nearly impossible for bacteria to evolve resistance. The antibiotic works by disrupting protein production and DNA structure, rendering random mutations ineffective.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Autoimmune liver diseases like AIH, PBC, and PSC exhibit distinct cellular targets and inflammatory profiles. Single-cell RNA sequencing and spatial transcriptomics provide new insights into their pathogenesis and potential treatment strategies.
Researchers discovered that co-administering two anti-CADM1 antibodies, 3E1 and 9D2, enhances tumor suppression by relocating CADM1 proteins to stable cellular structures. This relocation triggers endocytosis, leading to increased drug uptake by cancer cells.
Researchers at Hokkaido University have developed a comprehensive derivative synthesis method to find new antimicrobial drugs. They identified eight analogs possessing strong MraY inhibitory and antibacterial activity, with one showing promising effectiveness in mouse infection models.
Researchers have discovered an antibody fragment that can bind to abnormal light chains, stabilizing them and preventing their aggregation. This finding has the potential to provide a much-needed treatment for individuals with light chain amyloidosis, which currently has a poor prognosis.
Scientists have discovered a new hormone, CCN3, that helps maintain bone density and strength in breastfeeding women. In mice, CCN3 increased bone mass and strength, even when estrogen levels were low. The hormone also accelerated bone healing in fracture models, offering hope for treating osteoporosis and other bone conditions.
Co-circulation of Mayaro and chikungunya viruses has been observed in Roraima, Brazil's northernmost state, according to a recent study. The finding highlights the need for more effective epidemiological surveillance in the region. Deforestation and human activities may facilitate transmission in urban areas.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
The University of Texas at Arlington has awarded seven Interdisciplinary Research Program (IRP) grants totaling $140,000 to foster collaboration between groups. The grant increase represents a 40% boost over the previous year's funding.
Researchers at Trinity College Dublin have made a breakthrough in understanding how to improve vaccine responses against the potentially deadly MRSA bacterium. By targeting the immune-suppressive molecule IL-10, they improved the ability of vaccines to protect against infection and reduce bacterial clearance.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
Researchers identified nidogen-2 as a key driver of pancreatic cancer progression and metastasis. Blocking this molecule enhanced chemotherapy effectiveness and reduced spread in mouse models, suggesting a promising new treatment approach.
The University of Texas at Arlington's Junha Jeon is developing transition metal-free cross-coupling technologies using arynes to deliver medications safely and effectively. This project aims to improve the production of drugs, particularly for cancer treatment, by reducing impurities left behind by metals.
Researchers at Istituto Italiano di Tecnologia and EMBL unveiled how to modulate gene expression using small molecules. The study aims to develop new drugs specific to genetic mutations or alterations responsible for the onset of tumors or genetic diseases.
A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers develop a method that fuses AlphaFold's strengths with computer simulations based on physics laws to predict protein structures, enabling faster drug development. The approach filters down initial hypotheses to a more manageable set of structures, increasing the effectiveness of pharmaceuticals.
Researchers at U of T have developed a deep-learning model called PepFlow that can predict the full range of conformations for peptides, which are shorter than proteins but perform similar biological functions. The model combines machine learning and physics to capture precise and accurate conformations within minutes.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Scientists have generated a comprehensive map of gene targets regulated by HNF4A and HNF1A in human pancreatic beta cells and liver cells. The study identified novel gene targets in pancreatic beta cells that may play roles in regulating insulin secretion, providing valuable insights into potential therapeutic targets for diabetes.
Researchers at U of T have harnessed CRISPR to efficiently and precisely control RNA splicing, enabling the systematic interrogation of gene functions and correction of splicing deficiencies in diseases. This new tool allows for targeted activation or repression of alternative exons with high specificity.
A study by TUM researchers discovered four subtypes of Amyotrophic Lateral Sclerosis (ALS) with different molecular processes, including sex differences. The findings suggest repurposing an approved cancer drug targeting the MAPK pathway as a promising therapeutic approach for ALS.
Researchers at Purdue University have developed a patent-pending compound called HSN748 to treat drug-resistant acute myeloid leukemia (AML). The compound has been validated in tests with IU School of Medicine and demonstrated 100% survivability after 120 days. AML is a cancer that begins in bone marrow and can be difficult to treat du...
Researchers have identified a potent and unique way to kill drug-resistant bacteria using a repurposed compound called LEI-800. The compound targets the bacterial enzyme DNA gyrase, which is essential for bacterial growth and has not been targeted by existing antibiotics.
Researchers at OIST have discovered a novel treatment that effectively reverses the symptoms of Alzheimer's disease in mice. The treatment, PHDP5, targets the dynamin-microtubule interaction and restores communication between neurons inside synapses.
Researchers at Tokyo Institute of Technology have developed a novel synthesis strategy using quinolines as feedstock, enabling the creation of highly customizable drug candidates. The methodology leverages a light-sensitive borate intermediate to transform quinoline derivatives into various 2D/3D fused frameworks.
Researchers have identified a novel target downstream of parathyroid hormone signaling that suppresses bone formation. Gprc5a negatively regulates osteoblast proliferation and differentiation by partially suppressing BMP signaling, potentially increasing teriparatide effectiveness in non-responding patients.
A new study uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments. The research found two groups of patients with opposite immune responses and identified the genetic regulators involved.
Scientists have created mirror-image cyclodextrins in the laboratory, which could make it easier to formulate and deliver complex medications. These discoveries may also lead to improved treatment of cardiovascular diseases caused by atherosclerotic plaques.
Researchers developed tricks to slow down the receptor's closure and speed up freezing process, capturing critical images of kainate receptor in open configurations. These images provide information for drug developers to design more precise medicines for patients.
Researchers developed a rapid genotyping test for patients with central nervous system lesions, detecting key mutations associated with brain cancers in samples taken during a lumbar puncture. The test eliminated the need for surgical brain biopsies in seven cases and significantly accelerated time to treatment, from an average of 12 d...
Researchers at Virginia Tech have discovered a possible new pathway to treat colorectal cancer by targeting the NF-kB-inducing kinase (NIK) protein. The study, led by Irving Coy Allen, identifies changes in a significant signaling pathway in human patients and presents potential targets for therapeutics.
Scientists designed ring-shaped proteins targeting growth factor receptors to control human stem cell development. The resulting vascular networks formed tubes, healed, and absorbed nutrients, offering a new approach to repairing damaged hearts and kidneys.
Scientists at St. Jude Children's Research Hospital discovered that NLRC5 plays a crucial role as an innate immune sensor, triggering PANoptotic cell death. The findings suggest that targeting NLRC5 could lead to therapeutic development for infections, inflammatory diseases, and aging.
New research reveals that CRISPR/Cas9 gene editing tools have biases against cells from people of African ancestry, leading to false negative results. The study's findings highlight the importance of increasing genetic diversity in large-scale cell line libraries to mitigate this bias.
Researchers used machine learning to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles to identify four distinct molecular profiles of Alzheimer's Disease. These profiles were associated with varying levels of cognitive function and neuropathological features.
Researchers at The Jackson Laboratory discovered a cascade of molecules that help coordinate the attack of cytotoxic T-cells on tumors. Elevated levels of IL-3 reenergize these cells, signaling them to resume detecting and destroying tumors, with rare basophils playing a key role in this process.
Researchers compiled over 100 investigators' data from more than two dozen countries, increasing human spaceflight data by 10-fold. The results revealed longer-lasting molecular and physiologic changes distinct between crew members, targeting new areas for aerospace medicine.
A new chelator, L804, reduces off-target toxicity in PSMA radiopharmaceutical therapy by improving the bond between radioactive metal ions and targeting antibodies. This makes the therapy safer and more effective for patients.